全身炎症免疫营养评分判断晚期胃癌免疫治疗预后的价值分析

doi:10.11904/j.issn.1002-3070.2025.01.006

Abstract

Abstract: Objective The aim of this study was to explore the predictive value of the systemic inflammatory immune nutrition score(SIINS)for the prognosis of immunotherapy for advanced gastric cancer. Methods A retrospective analysis was conducted on the clinical data of 202 patients with advanced gastric cancer who received treatment with programmed death-1(PD-1)inhibitors at the Harbin Medical University Cancer Hospital from October 2018 to July 2022.The LASSO regression analysis was used to screen prognostic indicators,construct SIINS indicator,determine the optimal cutoff value for predicting prognosis using subject operating characteristic curves,and divide patients into the high SIINS and low SIINS groups.Independent prognostic factors for overall survival(OS)were determined using univariate and multivariate Cox regression analyses. Results Four indicators,including lymphocyte count,lactate dehydrogenase,and neutrophil lymphocytes,were selected to construct the SIINS index.The prognosis of patients in the high SIINS group was significantly lower than that in the low SIINS group(P＜0.05).The results of the multifactorial Cox regression analysis showed that the Eastern Cooperative Oncology Group(ECOG)score,Geriatric Nutritional Risk Index(GNRI),SIINS,treatment regimen,and number of treatment lines(P＜0.05)could serve as the independent predictive prognosis of immunotherapy for advanced gastric cancer. Conclusion SIINS can predict the prognosis of patients with advanced gastric cancer treated with PD-1 inhibitors.

Key words: Gastric cancer, Immunotherapy, Prognosis, Systemic-inflammatory-immune-nutritional-score

CLC Number:

R735.2

MA Ming, WANG Wanying, RUAN Yuli, LIU Chao, ZHANG Yanqiao, MA Zhigang. The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer[J]. Journal of Practical Oncology, 2025, 39(1): 39-48.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.01.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I1/39

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Smyth EC,Nilsson M,Grabsch HI,et al.Gastric cancer[J].Lancet,2020,396(10251):635-648.
3 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
4 Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:The KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.
5 Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial[J].Lancet,2021,398(10294):27-40.
6 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
7 Kim EY,Lee JW,Yoo HM,et al.The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio:which is better as a prognostic factor in gastric cancer[J].Ann Surg Oncol,2015,22(13):4363-4370.
8 Matsuoka T,Yashiro M.Biomarkers of gastric cancer:current topics and future perspective[J].World J Gastroenterol,2018,24(26):2818-2832.
9 Lim JU,Kang HS,Yeo CD,et al.Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors[J].J Thorac Dis,2021,13(5):2824-2832.
10 Gou M,Zhang Y,Liu T,et al.The prognostic value of pre-treatment hemoglobin(hb)in patients with advanced or metastatic gastric cancer treated with immunotherapy[J].Front Oncol,2021,11:655716.
11 Abravan A,Salem A,Price G,et al.Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy:a single-center large-cohort study[J].Acta Oncol,2022,61(2):163-171.
12 Shui Y,Li M,Su J,et al.Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer:a meta-analysis of 2,365 patients[J].Aging(Albany NY),2021,13(16):20585-20597.
13 Kubota T,Shoda K,Konishi H,et al.Nutrition update in gastric cancer surgery[J].Ann Gastroenterol Surg,2020,4(4):360-368.
14 Matsuda T,Umeda Y,Matsuda T,et al.Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma[J].BMC Cancer,2021,21(1):708.
15 Liu Q,Ma Z,Cao Q,et al.Perineural invasion-associated biomarkers for tumor development[J].Biomed Pharmacother,2022,155:113691.
16 Takei S,Kawazoe A,Shitara K.The new era of immunotherapy in gastric cancer[J].Cancers(Basel),2022,14(4):1054.
17 唐嘉黛,谢琳,李蓉,等.一种基于外周血炎症指标预测胃癌远处转移风险及预后的临床评分系统[J].现代肿瘤医学,2022,30(22):4108-4112.
18 段颖欣,霍俊杰.老年营养风险指数对新辅助化疗后胃癌患者疗效的预测价值[J].现代肿瘤医学,2024,32(2):289-296.
19 Gu L,Chen M,Guo D,et al.PD-L1 and gastric cancer prognosis:a systematic review and meta-analysis[J].PLoS One,2017,12(8):e0182692.
20 Chen X,Zhang H,Wang M,et al.Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients[J].Front Immunol,2022,13:783695.
21 Pinto M,Oliveira C,Machado JC,et al.MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile[J].Lab Invest,2000,80(12):1915-1923.
22 Miao L,Qi J,Zhao Q,et al.Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells[J].Theranostics,2020,10(2):498-515.
23 Coussens LM,Werb Z.Inflammation and cancer[J].Nature,2002,420(6917):860-867.
24 Lemery S,Keegan P,Pazdur R.First FDA approval agnostic of cancer site-when a biomarker defines the indication[J].N Engl J Med,2017,377(15):1409-1412.
25 齐京鹏,常彦祥,李斌,等.胃癌患者术前炎症标志物检测在患者预后评估中的意义[J].现代肿瘤医学,2014,22(4):861-864.
26 张茂林,杨芳,金相任,等.基于术前与术后中性粒细胞-淋巴细胞比值的组合预测胃癌患者的预后[J].现代肿瘤医学,2024,32(4):672-678.
27 Russo A,Russano M,Franchina T,et al.Neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),and outcomes with nivolumab in pretreated non-small cell lung cancer(NSCLC):a large retrospective multicenter study[J].Adv Ther,2020,37(3):1145-1155.
28 Watanabe K,Noma D,Masuda H,et al.Preoperative inflammation-based scores predict early recurrence after lung cancer resection[J].J Thorac Dis,2021,13(5):2812-2823.
29 Chen J,Shi X,Diao M,et al.A retrospective study of sepsis-associated encephalopathy:epidemiology,clinical features and adverse outcomes[J].BMC Emerg Med,2020,20(1):77.
30 王水莲,杨芳.预后营养指数对癌症患者预后的临床意义[J].现代肿瘤医学,2019,27(6):1083-1086.
31 Miholjcic TBS,Halse H,Bonvalet M,et al.Rationale for LDH-targeted cancer immunotherapy[J].Eur J Cancer,2023,181:166-178.
32 Ding P,Guo H,Sun C,et al.Combined systemic immune-inflammatory index(SII)and prognostic nutritional index(PNI)predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX:a prospective study[J].BMC Gastroenterol,2022,22(1):121.

[1]	LI Caizheng, ZHENG Jing, SU Qiaoli. Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2025, 39(1): 67-72.
[2]	KONG Hongqian, DONG Juan, WEN Hongmei, SHAO Ying, CHENG Huirong, YU Qiuli. Analysis of gastric cancer incidence and mortality in cancer registration areas of Yunnan province in 2020 and the trends from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 372-376.
[3]	XU Yaojie, CHANG Yihang, MO Piman, BAO Junjie. Research progress on disease characteristics and immune-related treatment of well-differentiated/dedifferentiated liposarcoma [J]. Journal of Practical Oncology, 2024, 38(4): 278-282.
[4]	SUN Lijun, DONG Dawei. Classification and prognosis of ovarian cancer based on platinum resistance related genes [J]. Journal of Practical Oncology, 2024, 38(3): 184-191.
[5]	LIAO Jun, LI Chunfeng, XUE Yingwei, ZU Hongliang. Research progress of lactate dehydrogenase in the diagnosis and treatment of gastric cancer [J]. Journal of Practical Oncology, 2024, 38(3): 200-206.
[6]	YANG Peng, LUO Jinmei, LUO Ping, XIE Xiaobo. An immune score model based on immune cell infiltration predicts the effects of immunotherapy and prognosis of early gastric cancer [J]. Journal of Practical Oncology, 2024, 38(2): 121-130.
[7]	ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2024, 38(1): 55-61.
[8]	GAO Yan, YAO Mengcheng, LI Zhefeng, HAN Xiaoyang, YUE Wentao. Single cell sequencing data reveal the diagnostic and predictive value of DMKN in ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(6): 478-484.
[9]	GAO Chaofeng, ZHAO Zekun, WEI Fengxian, SUN Yuan, ZHOU Zhiming, XU Xiaodong. Research progress on perioperative nutritional management for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(6): 519-523.
[10]	DENG Jielian, ZHENG Wei, LI Kangjie, ZHANG Cong, ZHANG Yuan, XIE Biao, ZHONG Xiaoni. Construction of a prognostic risk prediction model in liver cancer for macrophage related genes based on single-cell RNA-seq and bulk RNA-seq data [J]. Journal of Practical Oncology, 2023, 37(5): 403-410.
[11]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[12]	FU Xinya, HU Lingdan, ZHANG Zhijian, MA Xiumei. HPA promotes the invasion and metastasis of human gastric cancer cells by up-regulating MCP1/CCR2 [J]. Journal of Practical Oncology, 2023, 37(4): 329-336.
[13]	YAN Chunhui, YU Ling, HE Wenyuan, CUI Wenzhi, WANG Zhuocai, YAN Guangning. Expression of Galectin-9 and CD8 in osteosarcoma and their correlation with clinical pathological characteristics and prognosis [J]. Journal of Practical Oncology, 2023, 37(4): 337-343.
[14]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[15]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.

The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments